82VS

I am thrilled we at 82VS are partnering with CMT Research Foundation on this innovative approach to make medicines for Charcot-Marie-Tooth disease. CMT is the most common rare peripheral neuropathy with no FDA approved treatments to date. We are excited to work with CMTRF and leaders in the CMT field to make better CMT medicines. Thank you the the CMT Research Foundation team for their leadership and vision to creatively partner and support development of life-changing medicines for CMT. #makemedicinestogether #CMTResearch

Supporting early stage biotech is in our DNA! We've invested in 8 innovative young companies through the 2022 and 2023 Platinum Program and together with our pharma, services, and lab partners around the world we are collectively supporting their launch and growth. Learn more about our growing portfolio of Platinum Ticket investments. And stay tuned for the 2025 Platinum Program launch in the new year! Alloy Therapeutics, Inc., Goodwin, van den Boom & Associates LLC Eli Lilly and Company, Ono Venture Investment

Exciting times at 82VS, as we gear up and head to Arlington, Texas this week to attend and sponsor BioNTX! This event is a fantastic opportunity to connect with investors, entrepreneurs, scientists, and other professionals dedicated to advancing the biotech industry. If you're in North Texas, swing by the summit on Thursday to meet the team and to see - Errik Anderson, Managing Partner 82VS & CEO and Founder of?Alloy Therapeutics, discuss “The Role of Philanthropy in Global Health, Building Biotech Ecosystems and Driving Innovation” from 12:15pm to 1:15pm - Victor Stone M.D. (石井 喜英), General Partner 82VS & Head of Cell Therapies?Alloy Therapeutics?moderate a session for Entrepreneurs on "Navigating Innovation and Growth" from 3:25pm to 4:05pm Also, stop at our booth to learn more about our?Dallas-based Biotech Startup Academy (BSA)?and explore?NewCo funding?opportunities. #makemedicinetogether Looking forward to meeting everyone!??#BioNTX #Biotech #Innovation #82vs? ? https://lnkd.in/d2aAe2iJ

Aakha Biologics, is hiring! Aakha Biologics is building best-in-class antibody-based assets to redirect immune cells and tackle cancers that escape immune surveillance. This role presents an opportunity to learn from an exceptional founder, Hemanta Baruah. For more information on the role and Aakha, please visit our job board here: https://lnkd.in/edses2CZ

We are thrilled to announce that Ypsilon Therapeutics has been selected as a finalist for the Life Sciences Innovation Summit 2024, organized by J.P. Morgan Asset Management's Life Sciences Private Capital, Blue Horizon Advisors, and United AlSaqer Group. Being named a finalist is a testament to the hard work and dedication of our team. We look forward to presenting at the summit and connecting with industry leaders and investors! https://lnkd.in/ejdu7fnT

82VS and Alloy are thrilled to welcome Carlos into his newest role as a Venture Partner with 82VS. His exceptional skills in driving innovation, fostering growth, and operationalizing biotech companies have had a tremendous impact on 82VS, and we look forward to continuing to build the next generation of biotechs together!?